These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30229398)

  • 1. Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial.
    Romano P; Agena F; de Almeida Rezende Ebner P; Massakazu Sumita N; Kamada Triboni AH; Ramos F; Dos Santos Garcia M; Coelho Duarte NJ; Brambate Carvalhinho Lemos F; Zocoler Galante N; David-Neto E
    Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):189-199. PubMed ID: 30229398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
    Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD
    Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients.
    Graff J; Scheuermann EH; Brandhorst G; Oellerich M; Gossmann J
    Ther Drug Monit; 2016 Jun; 38(3):388-92. PubMed ID: 26829599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Exposure in Chinese Renal Allograft Recipients After Administration of EC-MPS.
    Chen B; Shao K; An HM; Shi HQ; Lu JQ; Zhai XH; Liu XX; Wang XH; Xu D; Zhou PJ
    J Clin Pharmacol; 2019 Apr; 59(4):578-589. PubMed ID: 30537048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
    Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
    Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients.
    Ettenger R; Bartosh S; Choi L; Zhu W; Niederberger W; Campestrini J; Bastien MC; Schmouder R
    Pediatr Transplant; 2005 Dec; 9(6):780-7. PubMed ID: 16269051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
    Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
    Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.
    Tornatore KM; Meaney CJ; Wilding GE; Chang SS; Gundroo A; Cooper LM; Gray V; Shin K; Fetterly GJ; Prey J; Clark K; Venuto RC
    Clin Pharmacokinet; 2015 Apr; 54(4):423-34. PubMed ID: 25511793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2011 Dec; 50(12):759-72. PubMed ID: 22087863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
    Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
    Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
    Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
    Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
    Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
    Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients.
    Tedesco-Silva H; Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Slade A; Schmouder R; Medina-Pestana JO
    Clin Transplant; 2010; 24(4):E116-23. PubMed ID: 20047618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.
    Tedesco-Silva H; Bastien MC; Choi L; Felipe C; Campestrini J; Picard F; Schmouder R
    Transplant Proc; 2005 Mar; 37(2):852-5. PubMed ID: 15848554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.
    Neumann I; Fuhrmann H; Kanzler M; Fang IF; Jaeger A; Graf H; Bayer P; Kovarik J
    Expert Opin Pharmacother; 2008 Apr; 9(6):879-86. PubMed ID: 18377332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients.
    Tang JT; de Winter BC; Hesselink DA; Sombogaard F; Wang LL; van Gelder T
    Br J Clin Pharmacol; 2017 Apr; 83(4):812-822. PubMed ID: 27753146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
    Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
    Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.